New Menopause Guidelines Give Hormone Therapy Its Strongest Endorsement Yet. The Fine Print Still Matters.

The American College of Obstetricians and Gynecologists issued its first full menopause clinical practice guideline since 2014 on Wednesday, and the headline recommendation is unambiguous: systemic hormone therapy gets ACOG's strongest possible endorsement for hot flashes, night sweats and the sleep disruption that comes with them, in women who have no contraindications. That is a higher confidence label than the guideline gives almost any other treatment on its list, and it matters because the strength of a recommendation is supposed to track the strength of the evidence behind it, not just the size of the benefit.

ACOG gave the same strong rating to SSRIs, SNRIs and neurokinin receptor antagonists such as fezolinetant, nonhormonal options for women who cannot or do not want to take hormones. Cognitive behavioral therapy, mindfulness training, exercise, hypnosis and acupuncture only earned conditional endorsements, a lower grade meaning the supporting evidence is thinner or the benefit varies more from patient to patient. Phytoestrogens and herbal supplements, long marketed as a gentler alternative, were explicitly not supported. For menopausal depression specifically, ACOG said the evidence is insufficient to recommend any treatment at all, a reminder that a guideline this broad still leaves real gaps.

The guideline also newly endorses conjugated estrogen paired with bazedoxifene as an alternative to standard estrogen progestogen regimens, according to summaries of the document published by Contemporary OB/GYN and Healio. Less clear from those early summaries is whether ACOG kept the age and timing window that has anchored hormone therapy guidance since the Menopause Society's 2022 position statement, which held that the risk benefit balance is favorable for women under 60 or within ten years of their last period, and less favorable for women starting later, when the absolute risks of stroke, blood clots and heart disease climb. That caveat is the hinge between two very different stories: a guideline that formalizes an existing, cautious consensus, or one that loosens it.

The breast cancer question is the sharpest edge of that evidence. A meta-analysis published in Lancet Oncology in July 2025 found that combined estrogen progestin therapy raised the risk of young onset breast cancer by roughly 10 percent, while estrogen alone, typically used by women who have had a hysterectomy, was associated with lower risk. That split result does not support a blanket claim that hormone therapy is now simply safe. It supports a narrower one: the regimen and the patient's surgical history change the calculation, which is why ACOG's exact wording on breast cancer risk by regimen type, not yet available in full to this reporter, is the passage worth reading before any patient or doctor treats this as a green light.

The timing of ACOG's guideline is also hard to separate from a contested regulatory reversal five weeks earlier. On November 10, 2025, the Food and Drug Administration, under Commissioner Marty Makary, said it would strip the black box warnings covering cardiovascular disease, breast cancer and dementia from estrogen containing hormone products, while keeping a narrower warning about endometrial cancer on estrogen only products, according to reporting by Harvard Health and EWN. Makary had convened and chaired the expert panel that recommended the change in July 2025, arguing that the original 2002 Women's Health Initiative trial, the study that triggered the warnings and a two decade drop in prescribing, had been misread and showed no statistically significant rise in breast cancer mortality, a position he had also staked out in his own 2024 book before joining the FDA.

That panel drew its own scrutiny. Politico reported that at least three invited speakers served as medical advisers to an advocacy group that had petitioned the FDA to drop the warning in the first place, and the agenda was not released publicly before the meeting, according to a summary from the Center for Research on Women and Newborns. None of that makes ACOG's new guideline wrong on the science. It does mean the guideline arrives inside a policy environment that was already leaning toward loosening restrictions on hormone therapy before ACOG's own evidence review was finished, which is useful context for reading how strong a signal strong actually is here.

The practical effect will likely show up first in prescribing, not in journals. Hims & Hers added menopause treatment to its platform in October 2025 as part of a push past $1 billion in annual revenue, and Midi Health, a menopause focused telehealth company, raised a $100 million round in February 2026 while reporting more than 230,000 patients. A guideline that tells doctors the benefits of hormone therapy strongly outweigh the harms for many women is a tailwind for that market, and the next thing worth tracking is whether prescriptions actually rise among women over 60, the group for whom the 2022 position statement, and possibly ACOG's new one, still counsel the most caution.